Commonwealth Financial Services LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,859 shares of the medical research company’s stock after buying an additional 165 shares during the quarter. Commonwealth Financial Services LLC’s holdings in Amgen were worth $484,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Talbot Financial LLC boosted its holdings in Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company’s stock valued at $11,153,000 after acquiring an additional 2,274 shares during the period. Swiss National Bank lifted its position in shares of Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock worth $513,033,000 after purchasing an additional 5,500 shares in the last quarter. Asset Advisors Investment Management LLC boosted its stake in shares of Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company’s stock valued at $11,578,000 after purchasing an additional 2,954 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock valued at $204,659,000 after purchasing an additional 35,785 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in shares of Amgen by 3.2% in the third quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company’s stock valued at $19,581,000 after purchasing an additional 1,872 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Stock Up 1.2 %
Amgen stock opened at $288.87 on Tuesday. The stock has a market capitalization of $155.28 billion, a price-to-earnings ratio of 36.99, a PEG ratio of 2.87 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a 50 day moving average of $271.06 and a two-hundred day moving average of $304.11. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.
Amgen Increases Dividend
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. TD Cowen increased their price objective on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Redburn Partners cut their price target on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Leerink Partners lowered their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Wolfe Research started coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $314.00.
Read Our Latest Stock Analysis on Amgen
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
- Five stocks we like better than Amgen
- What is a Dividend King?
- Gold Stocks Shine as Prices Hit Record Highs—Top 3 Picks
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Ally Financial: The Tugboat of Auto Finance Keeps Gaining Steam
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Cigna Misses EPS: What It Means for the Health Insurance Industry
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.